https://european-biotechnology.net/wp-content/uploads/2025/08/EU-Biotech-Act_1299854022_oynRQWpc8YPprtvb5tO9Tcqvgwp8kDJO-e1754461928206.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-06 06:34:072025-08-06 06:34:07EU Biotech Act: Have your say!
https://european-biotechnology.net/wp-content/uploads/2025/08/Ragon-Institute-PM-e1754387379667.png490869Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-08-05 09:50:122025-08-05 09:50:12ReiThera starts study on HIV vaccine
https://european-biotechnology.net/wp-content/uploads/2025/07/Bayer-Berlin_428625549_nMEd7NyJ7x7YYS941qTmpiKXLUeNZHgC-e1753694788880.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-28 09:27:482025-07-28 09:27:48Bayer targets leading position in HER2-positive NSCLC
https://european-biotechnology.net/wp-content/uploads/2025/07/Curevac_2ndgen-1030x683-1.jpg6831030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-24 06:20:492025-07-24 06:20:49From Brisbane to London to Paris: Vicebio´s Sanofi deal
https://european-biotechnology.net/wp-content/uploads/2025/07/Bildschirmfoto_2022-09-02_um_10.45.28.png167334Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-23 13:52:012025-07-24 07:32:02Abivax soars 500% on TOP-Line data
